Sino Biopharmaceutical Limited has announced significant progress in its innovation-driven development strategy, as highlighted in a recent voluntary announcement. The company's application for clinical trials of TQB6411, an EGFR/cMet Bispecific ADC, has been accepted by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. Additionally, TQB2922, an EGFR/cMet Bispecific Antibody, has entered Phase I trials, while TQB3002, a Fourth-Generation EGFR Inhibitor, received approval for clinical trials from the United States Food and Drug Administration (FDA) in November of the previous year. These advancements underscore the company's commitment to innovation and its ongoing efforts to enhance its pipeline of clinical-stage assets with First-In-Class and Best-In-Class potential.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。